Navigation Links
Scientists discover cells critical to childhood leukemia
Date:1/21/2010

Scientists at The Royal Melbourne Hospital and the University of Melbourne in Australia have discovered the cells that cause a common type of childhood leukaemia T cell Acute Lymphoblastic Leukaemia (T-ALL). Targeting of these cells may lead to improved treatments for this disease and help prevent relapse.

The team, led by Dr Matthew McCormack and Dr David Curtis of the Rotary Bone Marrow Research Laboratories and the University's Department of Medicine at The Royal Melbourne Hospital, made the discovery whilst studying mice prone to developing this leukaemia.

The results have been published online today by the prestigious international journal Science.

The team found that with irradiation treatment in animal models, over 99 per cent of cells in the thymus were killed, but these stem cell-like cells persisted and rapidly recovered. This suggests that these cells may survive therapy and be responsible for relapsed disease following treatment.

Currently, children with T-ALL are given extended therapy over two to three years in an attempt to stop a relapse. More targeted therapy on the thymus cells could reduce the length and toxicity of treatment and prevent relapse.

Dr McCormack, a leading international expert on childhood leukaemia, said: "The cellular origins of this leukaemia are not well understood. Our discovery that these cells are similar to normal stem cells explains why they are capable of surviving for long periods. It also explains why they are remarkably resistant to treatment."

Approximately 50 new cases of T-ALL are diagnosed every year in Australia, two thirds of these in children or adolescents. Adults also contract T-ALL, and the majority succumb to resistant or relapsed disease.

Dr Curtis, a Clinical Haematologist and head of the Leukaemia Research Program at The Royal Melbourne Hospital, said: "The identification of these cells provides an important target for the development and testing of new treatments for patients with T cell Acute Lymphoblastic Leukaemia."

The team will now focus on novel treatments capable of killing these cells, which may lead to clinical trials within the next five years.


'/>"/>

Contact: Rebecca Scott
rebeccas@unimelb.edu.au
61-383-440-181
University of Melbourne
Source:Eurekalert

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... , ... “Epilepsy Awareness,” which can be found at the ... about epilepsy, bearing down on the social stigma and lack of public education ... within their lifetime. With such a large percentage of people affected, it’s critically ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, LLC (PER®) ... on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February 24, 2017. ... to have Amy E. Herman present at this year’s conference, her unprecedented knowledge ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... gender, and geographic lines. The goal of Castlewood Treatment Centers has always been ... accessible to as many people as possible. In that spirit, Castlewood has ...
(Date:12/5/2016)... ... December 05, 2016 , ... Dr. Barry M. Weintraub, one of New York ... participated in the 36th Annual Cutting Edge Aesthetic Symposium at the Waldorf Astoria in ... that perfect, yet natural-looking, nose. Dr. Weintraub, who is world-renowned for his expertise in ...
(Date:12/5/2016)... ... 2016 , ... Sideline Products is a Southern York County Pennsylvania-based premier designer ... and the horse. Smaller saddles can pinch and irritate the horse creating safety issues ... properly fitted western saddle so it does not impact the comfort or performance of ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... Dec. 5, 2016  Breckenridge Pharmaceutical, Inc. announced ... marketing agreement with development and manufacturing partner Gland ... the terms of this agreement, Breckenridge will market ... the United States . The ... ANDA. The products cover a wide range of ...
(Date:12/5/2016)... 2016  Sharn Anesthesia Inc. announced today that it ... partner for Salter Labs.  The company also received the ... of outstanding sales performance. Salter Labs is ... care, including the market gold standard ECO 2 ... of the Parker Flex-Tip® Endotracheal Tube, which is a ...
Breaking Medicine Technology: